We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App





Siemens Healthineers Showcases Advanced Diagnostics Analyzers

By LabMedica International staff writers
Posted on 07 Feb 2018
Print article
Image: The Atellica range was highlighted at MEDLAB 2018 (Photo courtesy of Siemens Healthineers).
Image: The Atellica range was highlighted at MEDLAB 2018 (Photo courtesy of Siemens Healthineers).
Siemens Healthineers (Erlangen, Germany) showcased its Atellica range of advanced diagnostics analyzers at MEDLAB Middle East, the world’s largest attended laboratory and IVD exhibition and conference, held from February 5-8, 2018 in Dubai, UAE.
 
Leading laboratory experts, scientists, researchers and clinicians converged at the three-day event to exchange and share their experiences and research results on all aspects of laboratory medicine and clinical research while companies showcased the latest innovations, products and cutting-edge technologies available in the IVD, medical laboratory and healthcare market. Among the exhibitors at the event was Siemens Healthineers, which displayed its Atellica range of flexible and scalable automation-ready immunoassay and chemistry analyzers, fully-automated high-volume coagulation system, and automated urinalysis system.
 
At MEDLAB Middle East 2018, Siemens exhibited its Atellica Solution, which is designed to address common clinical laboratory challenges and integrates immunoassay and clinical chemistry analyzers with the new standard in sample-management technology so laboratories can focus on driving better outcomes. Also on display was the company’s Atellica COAG 360 System, a fully automated high volume coagulation analyzer that simplifies lab operations by unifying five methodologies on one platform, streamlines hemostasis workflow through intelligent reagent and consumable management, and delivers infinite possibilities by being the first to integrate LOCI technology in specialty hemostasis testing.
 
Siemens also showcased the Atellica 1500 Automated Urinalysis System, which combines the CLINITEK Novus Analyzer and the new Atellica UAS 800 Analyzer. The truly digital automated urinalysis system sets new standards for accuracy and efficiency and allows laboratories to manage more samples with less staff in shorter time without compromising on high-quality results. The company also showcased the Atellica MDX 160 Molecular System, which provides innovation in the molecular laboratory by improving workflow and consolidation while providing for flexibility and customization.
 
Other instruments showcased by Siemens at this year’s MEDLAB Middle East included the Atellica NEPH 630 System, a mid-volume dedicated nephelometric analyzer that simplifies lab operations in specialty protein testing, and the handheld epoc Blood Analysis System which goes wherever patients are located and provides lab-quality results on the spot. Siemens also demonstrated the Atellica PM 1.0 Software, which is the only lab management system that allows the management of laboratory’s processes, including alerts, remote management of instruments, and monitoring of onboard inventory and testing progress—all from one screen.
 
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HbA1c Test
HbA1c Rapid Test
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.